


FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.448C10		APPLICATION NO. Not Assigned	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Martin A. Cheever and Mary L. Disis			
				FILING DATE August 21, 2003		GROUP ART UNIT Not Assigned	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
ALH 	AA	3,766,162	10/1973	Spector	260	112.R	
	AB	3,791,932	02/1974	Schuurs et al.	195	103.5R	
	AC	3,817,837	06/1974	Rubenstein et al.	195	103.5R	
	AD	3,850,752	11/1974	Schuurs et al.	195	103.5R	
	AE	3,901,654	08/1975	Gross	23	230.B	
	AF	3,935,074	01/1976	Rubenstein et al.	195	103.5R	
	AG	3,984,533	10/1976	Uzgiris	424	12	
	AH	3,996,345	12/1976	Ullman et al.	424	12	
	AI	4,034,074	07/1977	Miles	424	1	
	AJ	4,098,876	07/1978	Piasio et al.	424	1	
	AK	4,233,402	11/1980	Maggio et al.	435	7	

FOREIGN PATENT DOCUMENTS					
DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
			YES	NO	
ALH	AL	WO 90/14357	11/1990	PCT	
ALH	AM	WO 91/02062	02/1991	PCT	
	AN				
	AO				
	AP				

OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
ALH	AQ	Alper et al., "The Presence of c-erbB-2 Gene Product-related Protein in Culture Medium Conditioned by Breast Cancer Cell Line SK-BR-3," <i>Cell Growth & Differentiation</i> 1:591-599, 1990.
ALH	AR	Bargmann et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein," <i>Nature</i> 319:226-230, 1986.
ALH	AS	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185(^HER2) Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer," <i>Journal of Clinical Oncology</i> 14(3): 737-744, 1996.

EXAMINER <div style="text-align: center;">/Anne Holleran/</div>	DATE CONSIDERED <div style="text-align: center;">(06/26/2006)</div>
--	--

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.448C10		APPLICATION NO. Not Assigned	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Martin A. Cheever and Mary L. Disis			
				FILING DATE August 21, 2003		GROUP ART UNIT Not Assigned	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
ALH	AA	4,452,901	Gordon et al.	436	506		
ALH	AB	5,320,947	Cheever et al.	435	29		
ALH	AC	5,401,638	Carney et al.	435	7.23		
	AD	5,958,784	Benner	436	86		
	AE	5,985,553	King et al.	435	6		
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS					
DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
			YES	NO	
AL					
AM					
AN					
AO					
AP					

OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
ALH	AQ	Ben-Mahrez et al., "Circulating Antibodies Against C-myc Oncogene Product In Sera Of Colorectal Cancer Patients," <i>Int. J. Cancer</i> 46: 35-38, 1990.
ALH	AR	Bishop and Orosz, "Limiting Dilution Analysis For Alloreactive, TCGF-Secretory T Cells. Two Related LDA Methods That Discriminate Between Unstimulated Precursor T Cells and In Vivo-Alloactivated T Cells," <i>Transplantation</i> 47(4): 671-677, 1989.
ALH	AS	Bodmer, W., "T-Cell Immune Responses to Cancer--A New Look," <i>Human Immunology</i> 30:259-261, 1991.

EXAMINER <div style="text-align: right;">/Anne Holleran/</div>	DATE CONSIDERED (06/26/2006)
---	---------------------------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.448C10		APPLICATION NO. Not Assigned	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Martin A. Cheever and Mary L. Disis			
				FILING DATE August 21, 2003		GROUP ART UNIT Not Assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	ALH	AA	Igelhart et al., "Increased erbB-2 Gene Copies and Expression in Multiple Stages of Breast Cancer," <i>Cancer Research</i> 50: 6701-6707, 1990.				
		AB	Ioannides et al., "Antigens Recognized by T cells in Ovarian Cancer," in Abstracts of the Fourth International Conference of Anticancer Research, 21-25 Oct. 1992, Rethymnon, Crete, Greece, p. 1870.				
		AC	Ioannides et al., "CTL Clones Isolated from Ovarian Tumor Infiltrating Lymphocytes can Recognize Peptides with Sequences Corresponding to the HER2/neu Gene Product," <i>FASEB Journal</i> 6: A1404, Abstract No. 2711, 1992.				
		AD	Ioannides et al., "Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2/neu Proto-oncogene," <i>Cell. Immunol.</i> 151: 225-234, 1993.				
		AE	Ioannides et al., "Cytotoxic T-Cell Clones Isolated from Ovarian Tumour Infiltrating Lymphocytes Recognize Common Determinants on Non-Ovarian Tumour Clones," <i>Scand. J. Immunol.</i> 37: 413-424, 1993.				
		AF	Ioannides et al., "T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy," <i>Molecular Carcinogenesis</i> 6: 77-82, 1992.				
		AG	Ioannides, Abstracts Fourth International Conference of Anticancer Research 21-25 Oct. 1992 p. 1870.				
		AH	Ioannides, "Antigens and vaccines of female genital cancers (Meeting abstract)," Cancerlit Database Abstract No. ICDB/93690682, 1992.				
		AI	Ioannides, et al., "Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2/neu Proto-oncogene," <i>Cell. Immunol.</i> 151:225-234, 1993.				
		AJ	Ioannides, Society for Biological Therapy 1992 Annual Meeting, p. 27 Oct. 29-Nov. 1, 1992.				
	AK	Kallioniemi et al., "ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization," <i>Proc. Natl. Acad. Sci.</i> 89: 5321-5325, 1992.					
EXAMINER <div style="text-align: right; font-size: 1.2em;">/Anne Holleran/ (06/26/2006)</div>				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.448C10		APPLICATION NO. Not Assigned	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Martin A. Cheever and Mary L. Disis			
				FILING DATE August 21, 2003		GROUP ART UNIT Not Assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
				YES NO			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
ALH ↓	AA	Kerns et al., "c-erbB-2 Expression In Breast Cancer Detected by Immunoblotting and Immunohistochemistry," <i>Journal of Histochemistry and Cytochemistry</i> 38(12): 1823-1830, 1990.					
	AB	Laemmli, U., "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4," <i>Nature</i> 227: 680-685, 1970.					
	AC	Leitzel et al., "Elevated Soluble c-erbB2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients," <i>Journal of Clinical Oncology</i> 10(9): 1436-1443, 1992.					
	AD	Lichtenstein et al., "Effects of .beta.-2 Microglobulin Anti-sense oligonucleotides on Sensitivity of HER2/neu Oncogene-Expressing and Nonexpressing Target Cells to Lymphocyte-Mediated Lysis," <i>Cellular Immunology</i> 141: 219-232, 1992.					
	AE	Lippman, M., "Potential Contributions of Breast Cancer Biology to Management of Breast Cancer," <i>Advances in Oncology</i> 8(3): 26-28, 1992.					
	AF	Lippman, M., "Potential Contributions of Breast Cancer Biology to Management of Breast Cancer", <i>Advances in Oncology</i> 8(3): 26-28, 1992.					
	AG	Maguire and Greene, "The neu (c-erbB-2) Oncogene," <i>Seminars in Oncology</i> 16(2): 148-155, 1989.					
	AH	Margalit et al., "Prediction Of Immunodominant Helper T Cell Antigenic Sites From The Primary Sequence," <i>Journal of Immunology</i> 138(7): 2213-2229, 1987.					
	AI	McGlynn et al., "Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors," <i>Eur. J. Biochem.</i> 207: 265-275, 1992.					
	AJ	McKenzie et al., "Induction of Antitumor Immunity by Immunization with a Vaccinia Virus Vector Expressing and Oncogene-encoded Product," in <i>Vaccines</i> 88, Cold Spring Harbor Laboratory, 1988, pp. 19-23.					
AK	Mietzner et al., "Purification and Characterization of the Major Iron-Regulated Protein Expressed By Pathogenic Neisseriae," <i>Journal of Experimental Medicine</i> 165: 1041-1057, 1987.						
EXAMINER /Anne Holleran/ (06/26/2006)				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.448C10		APPLICATION NO. Not Assigned	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Martin A. Cheever and Mary L. Disis			
				FILING DATE August 21, 2003		GROUP ART UNIT Not Assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
ALH ↓	AA	Mori et al., "In Vitro and in vivo Release of Soluble erbB-2 Protein from Human Carcinoma Cells," <i>Japanese Journal of Cancer Research</i> 81: 489-494, 1990.					
	AB	Paik et al., "Pathologic Findings From the National Surgical Adjuvant Breast and Bowel Project: Prognostic Significance of erbB-2 Protein Overexpression in Primary Breast Cancer," <i>Journal of Clinical Oncology</i> 8(1): 103-112, 1990.					
	AC	Parker et al., "Sequence Motifs Important For Peptide Binding To The Human MHC Class I Molecule, HLA-A2," <i>Journal of Immunology</i> 149(11): 3580-3587, 1992.					
	AD	Press et al., "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues," <i>Oncogene</i> 5: 953-962, 1990.					
	AE	Raines and Ross, "Platelet-derived Growth Factor. I. High Yields Purification and Evidence for Multiple Forms," <i>Journal of Biological Chemistry</i> 257(9): 5154-5159, 1982.					
	AF	Riberdy and Cresswell, "The Antigen-Processing Mutant T2 Suggests a Role for MHC-Linked Genes in Class II Antigen Presentation," <i>Journal of Immunology</i> 148(8):2586-2590, 1992.					
	AG	Rothbard and Taylor, "A sequence pattern common to T cell epitopes," <i>EMBO Journal</i> 7(1): 93-100, 1988.					
	AH	Semba et al., "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma," <i>Proc. Natl. Acad. Sci. USA</i> 82: 6497-6501, 1985.					
	AI	Spies et al., "A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway," <i>Nature</i> 348: 744-747, 1990.					
	AJ	Stern et al., "Oncogene Activation of p185(^{neu}) Stimulates Tyrosine Phosphorylation In Vivo," <i>Molecular and Cellular Biology</i> 8(9): 3969-3973, 1988.					
AK	Trowsdale et al., "Sequence encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters," <i>Nature</i> 348: 741-744, 1990.						
EXAMINER /Anne Holleran/ (06/26/2006)				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.448C10		APPLICATION NO. Not Assigned	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Martin A. Cheever and Mary L. Disis			
				FILING DATE August 21, 2003		GROUP ART UNIT Not Assigned	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS					
DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
			YES	NO	

OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
ALH 	AA	Weiner et al., "A point mutation in the neu oncogene mimics ligand induction of receptor aggregation," <i>Nature</i> 339: 230-231, 1989.
	AB	Wide, L., "Solid Phase Antigen-Antibody Systems," in Radioimmunoassay Methods, Kirkham and Hunter (eds.), 1973, pp. 405-412.
	AC	Wisdom, G.B., "Enzyme-Immunoassay," <i>Clin. Chem.</i> 22(8): 1243-1255, 1976.
	AD	Yamamoto et al., "Similarity of protein encoded by the c-erb-B-2 gene to epidermal growth factor receptor," <i>Nature</i> 319: 230-234, 1986.
	AE	Zabrecky et al., "The Extracellular Domain of p185/neu Is Released from the Surface of Human Breast Carcinoma Cells, SK-BR-3," <i>Journal of Biological Chemistry</i> 266(3): 1716-1720, 1991.
	AF	
	AG	
	AH	
	AI	
	AJ	
	AK	

EXAMINER <div style="text-align: center; margin-top: 10px;">/Anne Holleran/ (06/26/2006)</div>	DATE CONSIDERED <div style="text-align: center; margin-top: 10px;">06/26/2006</div>
--	---

*** EXAMINER:** Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).